WHO Model Prescribing Information: Drugs Used in Anaesthesia
(1989; 60 pages) [French] View the PDF document
Table of Contents
View the documentPreface
View the documentIntroduction
Open this folder and view contentsPremedication
Open this folder and view contentsGeneral anaesthetics and oxygen
Open this folder and view contentsLocal anaesthetics
Open this folder and view contentsNon-opioid analgesics
Open this folder and view contentsOpioid analgesics and antagonists
Close this folderMuscle relaxants and cholinesterase inhibitors
View the documentGallamine
View the documentSuxamethonium
View the documentNeostigmine
Open this folder and view contentsBlood substitutes
Open this folder and view contentsSolutions for correcting water and electrolyte imbalance
Open this folder and view contentsAntacid for use in obstetric practice
View the documentAnaesthesia at the District Hospital
View the documentSelected WHO publications of related interest
View the documentBack cover
 

Neostigmine

Group: cholinesterase inhibitor
Injection: 0.5, 2.5 mg (metilsulfate)/ml in 1-ml ampoule

General information

Neostigmine is a cholinesterase inhibitor that raises the concentration of acetylcholine at the myoneural junction and other cholinergic nerve endings. Administered parenterally, the effect of a single dose persists for 2-4 hours. It is destroyed by plasma esterases and excreted in the urine.

Clinical information

Uses

• To counteract the effect of non-depolarizing muscle relaxants administered during surgery.

• Treatment of postoperative non-obstructive urinary retention.

Dosage

Reversal of muscle relaxation

Adults: 2.5 mg by i.v. injection. Supplements of 0.5 mg may be administered as necessary up to a maximum of 5 mg. Atropine sulfate (600-1200 micrograms i.v.) administered immediately beforehand prevents autonomic excitation.

Children: 40 micrograms/kg i.v. after atropine sulfate (20 micrograms/kg i.v.) administered as above.

Titration of the required dose using a peripheral-nerve stimulator is advisable in small children and severely ill patients.

The initial dose should be reduced in patients with bronchial asthma, postoperative atelectasis, bradycardia, atrioventricular block and other cardiac dysrhythmias, epilepsy and parkinsonism.

Postoperative non-obstructive urinary retention

Adults: 500 micrograms i.m. or subcutaneously initially, repeated every 3 hours for at least 15 hours once the patient has voided the bladder. If urine is not passed within 1 hour of the initial dose the patient’s bladder should be catheterized. Cystoscopy is indicated if retention persists.

Contraindications

• Hypersensitivity to neostigmine.
• Peritonitis.
• Mechanical obstruction of the intestinal or urinary tracts.

Precautions

Equipment for resuscitation and mechanically assisted respiration should be immediately available.

Neostigmine should be given only after halothane or ether administration has been discontinued.

Adequate ventilation must be maintained since respiratory acidosis predisposes the patient to cardiac dysrhythmias.

Use in pregnancy

Neostigmine should be administered only when the need outweighs any possible risk to the fetus. Premature labour has been induced following intravenous administration near term.

Adverse effects

Neostigmine may produce signs of excessive cholinergic activity, including nausea and vomiting, increased salivation, diarrhoea, abdominal cramps, cardiac dysrhythmias, syncope and hypotension.

Rash, urticaria and anaphylaxis have been reported.

Drug interactions

Neostigmine potentiates the effect of depolarizing muscle relaxants. It should therefore not be used in conjunction with suxamethonium.

Overdosage

Sudden death may occur as a result of cardiac arrest. More frequently a “cholinergic crisis” is induced, characterized by nausea, vomiting, diarrhoea, excess salivation and rapidly progressive paralysis. Ventilation must be mechanically assisted until spontaneous breathing returns. Atropine (1 mg i.v.) serves to block the autonomic effects.

Storage

Neostigmine should be stored in ampoules protected from light, and should not be allowed to freeze.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 29, 2018